Filter
105
Filtered Results: 105
Text search:
visceral
leishmaniasis
(VL)
Featured
Recommendations
4
New Publications
13
Language
Document type
No document type
29
Studies & Reports
27
Videos
11
Resource Platforms
9
Guidelines
8
Fact sheets
7
Strategic & Response Plan
5
Manuals
3
Infographics
3
Training Material
2
Online Courses
1
Countries / Regions
Global
42
Ethiopia
10
Latin America and the Carribbean
7
Nepal
6
Kenya
5
Bangladesh
5
India
5
Sudan
4
Middle East and North Africa
3
Brazil
3
South Sudan
3
Asia
2
South–East Asia Region
2
Western and Central Europe
2
Paraguay
2
Uganda
2
Greece
2
Somalia
2
North Macedonia
1
Mexico
1
Turkey
1
China
1
Syria
1
Iran
1
Albania
1
Malawi
1
Morocco
1
Africa
1
Cambodia
1
Jordan
1
Saudi Arabia
1
North America
1
Tunisia
1
East and Southern Africa
1
Bolivia
1
Lebanon
1
Eastern Europe
1
Georgia
1
Iraq
1
Myanmar / Burma
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Leishmaniasis
21
Disease Prevention & Control
15
Statistics
9
Guidelines
7
Policies & Guidelines HIV & TB
5
Studies & Reports
5
Policies
4
Dermatology
3
Vector Control
2
Health System Strengthening
2
NTDs & Others
2
Parasitology
2
Pharmacy & Technologies
2
Paediatrics
1
Pediatrics
1
Chagas
1
Drugs & Medical Equipment
1
Capacity Building
1
Gynaecology & Obstetrics
1
Maternal Health
1
HIV & STI
1
Toolboxes
Information & Education Material (IEC)
22
Studies & Reports
19
Leishmaniasis
14
Statistics & Facts
7
Overview, Studies & Reports
5
NTDs General
4
Vector control
4
Community Health Workers CHW
3
Clinical Aspects & Diagnostics
3
Information & Education Material (IEC)
3
Opportunistic Infections
2
HIV
2
Others
2
Strategies & Roadmaps
2
Capacity Building & Resource platforms
2
Clinical Aspects, Treatment & Prevention
1
Clinical Aspects
1
Treatment Guidelines HIV
1
Climate & Health
1
Global Impact: Socio-economic, health services, TB & HIV
1
Pharmacy
1
Essential Medicines
1
General documents One Health
1
Infectious Diseases
1
Health Impact & Climate Change
1
Chagas
1
Capacity Building & Resources
1
Clinical Aspects & Diagnostics
1
Studies & Reports
1
Studies & Reports
1
Yaws & other Endemic Treponematoses
1
Antiretroviral Treatment ART
1
Reports & Studies Children HIV
1
Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ...
Visceral leishmaniasis is an important disease in East Africa where recurrent outbreaks occur. Leishmania-HIV coinfected people have high chance of developing the full-blown clinical disease, and high relapse and mortality rates. Poverty, malnutrition and population movements in endemic areas increa...
In the Indian state of Bihar, visceral leishmaniasis (VL) is a major public health issue that has been aggravated by the rising incidence of new Human immunodeficiency virus (HIV) infections. In endemic areas, the risk of VL infections in patients living with HIV (PLHIV) is higher. It is important t...
The results of a large-scale systematic review and meta-analysis have published in PLOS Neglected Tropical Diseases. This research aimed to collate all reported serious adverse events (SAE) in visceral leishmaniasis (VL) clinical trials and quantify the incidence of mortality during the first 30 day...
During the Programme Managers’ Review Meeting of Central and East Africa and South-East Asia (online meeting, June 2022), experts proposed additional regional and national subtargets related to VL incidence, as defined below. These targets can be revisited as progress is reviewed and access to dia...
Weekly epidemiological record / Relevé épidémiologique hebdomadaire
22 SEPTEMBER 2017, 92th YEAR / 22 SEPTEMBRE 2017, 92e ANNÉE
No 38, 2017, 92, 557–572
There are 4 main forms of the disease: visceral leishmaniasis (VL, also known as kala-azar); post-kala-azar dermal leishmania...
22 SEPTEMBER 2017, 92th YEAR / 22 SEPTEMBRE 2017, 92e ANNÉE
No 38, 2017, 92, 557–572
There are 4 main forms of the disease: visceral leishmaniasis (VL, also known as kala-azar); post-kala-azar dermal leishmania...
Leishmaniasis is a parasitic disease caused by intracellular protozoan parasites of the genus Leishmania (Trypanosomatidae family); it is endemic in more than 98 countries worldwide [1]. Visceral (VL) and cutaneous (CL) leishmaniasis are the most common forms of the disease. VL causes a systemic dis...
We developed an integrated vector surveillance (IVS) proposal for cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL) in the Americas, based on eco-epidemiological studies conducted by researchers of the Leishmaniasis Research Network of Argentina. For CL, the transmission was explained in ...
Surveillance mondiale de la leishmaniose: 2021, évaluation de l’impact de la pandémie de COVID-19
The aims of this report are to update the results of the GHO leishmaniasis indicators reported by Member States to WHO up to 2021, to describe specific indicators of gender and age distribution, re...
Leishmaniasis is a vector-borne disease with a broad global distribution and an increasing number of recorded cases worldwide. However, it is still one of the world's most neglected diseases. Over the last decades, the disease has been found to expand geographically with a global increase of cases o...
The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with...
Website last accessed on 04.06.2023
Youtube Video
Website last accessed on 04.06.2023
Youtube Video
Video last accessed on 04.06.2023
Video Dailymotion
Frequently Asked Questions on Visceral Leishmaniasis
Kala-azar (Visceral leishmaniasis),PKDL:Epidemiology,clinical features, investigations and treatment
Last accessed on 14.05.2023
Youtube - Video
There are 3 main forms of leishmaniases: visceral (the most serious form because it is almost always fatal without treatment), cutaneous (the most common, usually causing skin ulcers), and mucocutaneous (affecting mouth, nose and throat).
Leishmaniasis is caused by protozoan parasites which are tra...
Leishmaniasis is an important worldwide disease with a
zoonotic potential that presenting visceral and cutaneous
clinical forms. The domestic dog is seen as the main reservoir of Leishmania spp. and for this reason, it is the target of
the control program in some countries. The health professiona...
Website last accessed on 04.06.2023
Treatment options for Visceral Leishmaniasis in HIV-coinfected people include oral miltefosine; find additional information on diagnosis and ART treatment.
Leishmaniasis is a vector-borne tropical/subtropical disease caused by an intracellular parasite transmitted to humans by sand fly bite. It is endemic in Asia, Africa, the Americas, and the Mediterranean region. Worldwide reports include 1.5–2 million new cases each year, more than 300 million at ...
